Drug Profile
Latanoprost/netarsudil - Alcon
Alternative Names: AR-13324/latanoprost; Latanoprost/AR-13324; Latanoprost/netarsudil-mesylate; Netarsudil and latanoprost ophthalmic solution - Alcon; Netarsudil-mesylate/latanoprost; Netarsudil/latanoprost; Netarsudil/latanoprost ophthalmic solution - Alcon; PG-324; Rocklatan; Roclanda; Roclatan; STN 1014000Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Aerie Pharmaceuticals
- Developer Alcon; Santen Pharmaceutical
- Class Antiglaucomas; Cyclopentanes; Eye disorder therapies; Isoquinolines; Prostaglandins; Small molecules
- Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors; Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Ocular hypertension; Open-angle glaucoma
- Registered Glaucoma
Most Recent Events
- 31 Jan 2023 Registered for Glaucoma in Asia (Ophthalmic) (Santen Pharmaceutical pipeline; November 2023)
- 31 Jan 2023 Launched for Ocular hypertension in Germany (Ophthalmic) (Santen Pharmaceutical pipeline, February 2023)
- 31 Jan 2023 Launched for Open-angle glaucoma in Germany (Ophthalmic) (Santen Pharmaceutical pipeline, February 2023)